The United States Patent and Trademark Office has issued a patent covering the methods of cancer treatment with Lorus Therapeutics' novel therapy, IL-17E. Treatment methods with IL-17E include single and combination therapy along with ...
Tags: IL-17E, Lorus Therapeutics, Cancer Therapy, US Patent
Lorus Therapeutics has signed a collaboration agreement with Brock University to develop new anticancer drugs based on chemical derivatives of the natural compound pancratistatin.? As part of the collaboration,Lorus will test the ...
Tags: Lorus Therapeutics, Brock University, new anticancer drugs
The United States Patent and Trademark Office has issued a patent for Lorus Therapeutics' LOR-253, which covers composition of matter and methods of treating cancer. The patent was initially set to expire in May 2026 and latter was ...
Lorus Therapeutics has received first Japanese patent for its small molecule anticancer drug LOR-253 that will provide Lorus with exclusive rights to LOR-253 in Japan until 2023. The patent will provide protection for LOR-253 composition ...
The Canadian Intellectual Property Office has issued a patent for Lorus Therapeutics' cancer immunotherapy agent, IL-17E. The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, ...
Tags: patent, IL-17E, treatment of cancer